Both tumors presenting CX3CL1 mutations presented protein expression: HB32-mutated tumor exhibited weak cytoplasmic labeling and nuclear positivity in more than 50% of cells, whereas HB33-mutated showed strong cytoplasmatic labeling and nuclear positivity in 25% of cells (Figures 3A1–C1); in particular, HB33 exhibited great heterogeneity of histology and protein labeling. This evidence concerns the gene CX3CL1 and neoplasm.